 New York, New York--Newsfile Corp. - May 20, 2021 - PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals NASDAQ: AIKI, according to the companys Q1 report and a press release recently issued, is expecting positive results from human clinical trials of dual-action peptide receptor radionuclide therapy PRRT with notable insider buying in the open market displaying his strong belief in the Companys prospects.Developed by Weill Cornell Medicine... 